CRBP - Corbus Pharmaceuticals Holdings, Inc.
| Previous close | 5.45 |
| Open | 5.25 |
| Bid | 5.25 x 300 |
| Ask | 5.40 x 100 |
| Day's range | 5.35 - 5.60 |
| 52-week range | 4.85 - 9.95 |
| Volume | 376,730 |
| Avg. volume | 499,473 |
| Market cap | 305.712M |
| Beta | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 14 Aug 2017 - 18 Aug 2017 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.00 |
- Motley Fool•17 days ago
The Worst-Performing Marijuana Stocks in the Second Quarter
See which pot stocks took home this "doobie-ous" honor.
- Simply Wall St.•2 months ago
Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP): Are Analysts Optimistic?
Corbus Pharmaceuticals Holdings Inc’s (NASDAQ:CRBP): Corbus Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, focuses on the development and commercialization of various therapeutic products to treat inflammatory and fibrotic diseases.Read More...
- Associated Press•2 months ago
Corbus Pharmaceuticals: 1Q Earnings Snapshot
The Norwood, Massachusetts-based company said it had a loss of 21 cents per share. The drug developer posted revenue of $950,400 in the period. Its adjusted revenue was $950,000. Corbus Pharmaceuticals ...
- Marketwired•4 months ago
Corbus Pharmaceuticals Reports 2017 Financial Results and Provides Clinical Update
Corbus Pharmaceuticals Holdings, Inc. Advancing clinical studies in four rare and serious inflammatory diseases with significant morbidity and mortality and clear unmet medical needs Reported positive ...
- Marketwired•5 months ago
Corbus Pharmaceuticals to Present at the Cowen & Co. 38th Annual Health Care Conference
Corbus Pharmaceuticals Holdings, Inc. , a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive......
- Marketwired•5 months ago
Corbus Pharmaceuticals Announces Publication Demonstrating Lenabasum as First Drug to Stimulate Resolution of Innate Immune Responses in a Clinical Model
Study identifies lenabasum as important upstream trigger of resolution of innate immune responsesData provides mechanistic validation of positive clinical data reported from Company's Phase 2 clinical ...
- Marketwired•5 months ago
Corbus Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. , a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive......
Yahoo Finance•5 months agoStocks give up early gains, Trump signs budget bill
Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.
- Marketwired•5 months ago
Corbus Pharmaceuticals to Present at the 7th Annual LEERINK Partners Global Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. , a clinical-stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive......
- Marketwired•6 months ago
Corbus Pharmaceuticals Receives $25 Million Development Award from the Cystic Fibrosis Foundation to Support Phase 2b Clinical Study of Lenabasum
Award will support ~415-patient, 6-month Phase 2b study designed to provide clear evidence of clinical benefit for people with CFEvent rate of pulmonary exacerbations is sole primary efficacy endpoint ...
- Marketwired•6 months ago
Corbus Pharmaceuticals Announces Agreement with FDA on Phase 2b Cystic Fibrosis Study Design with Pulmonary Exacerbations as Sole Primary Endpoint
Multi-national Phase 2b is designed to provide clear evidence of clinical benefit of lenabasum in patients with CFStudy will enroll ~415 participants with CF 12 years of age and older regardless of underlying ...
- Market Realist•6 months ago
What Vermont Can Learn from Washington’s Marijuana Tax
In the previous article in this series, we saw that Vermont decriminalized recreational marijuana on January 22, 2018. With no legality covering the sale of marijuana and no tax revenues from these sales, what would motivate Vermont to legalize recreational marijuana?
- Market Realist•6 months ago
Vermont Legalizes Recreational Marijuana on January 22, 2018
On January 22, 2018, Vermont decriminalized the possession of marijuana for adults 21 and older. With increasing attention on the legalization of recreational marijuana in recent months, Vermont became the ninth state in the US to legalize marijuana for recreational purposes. This move comes almost six years after recreational marijuana became legal in Colorado and Washington.
- Market Realist•6 months ago
The Other Side of Legalizing Recreational Marijuana
While marijuana legalization for recreational use is just gaining attention around the world, it’s also facing strong opposition. According to some, legalizing marijuana will just increase substance abuse. Some groups are concerned that legalizing marijuana would make it even easier for young people to access the drug.
- Market Realist•6 months ago
What a Country Could Gain from Legalizing Recreational Marijuana
In the previous part of this series, we saw how the legalization of recreational marijuana could create related business opportunities. In this part, we’ll discuss the potential upside of recreational marijuana for a country like Canada. According to Deloitte, recreational marijuana alone could be a $5 billion industry initially, and it could go as high as $8.7 billion.
- Market Realist•6 months ago
The Marijuana Ecosystem’s Potential Business Opportunities
In the previous part of this series, we discussed Constellation Brands’ (STZ) investment in the marijuana industry. Given that legislative approval is the strongest driving factor behind the boost in the marijuana industry, companies have rushed to capitalize on the wave. Below, we discuss some of the business opportunities that could develop as a result of marijuana legalization.
- Market Realist•6 months ago
Is Investment in the Marijuana Space Picking Up?
In the previous part of this series, we saw that the alcohol industry could expect marijuana legalization for recreational purposes as an extension to their growth strategy. With too much confusion surrounding the legalities of the marijuana industry, some seasoned players appear highly optimistic about the future of recreational marijuana. Late last year, Constellation Brands (STZ) agreed to acquire a 9.9% stake in the Canada-based Canopy Growth for about $191.3 million.
- Market Realist•6 months ago
Why the Medical Marijuana Industry Is Growing
Must-Knows before Investing in the Marijuana Industry
- Market Realist•6 months ago
How Marijuana Acceptance Is Evolving Globally
It’s fascinating to see how the marijuana landscape around the world has evolved in the last three years. According to Canopy Growth (WEED.TO), Canada, Israel, the Czech Republic, Uruguay, and the Netherlands “established federally legal cannabis access regimes” in 2014. Globally, the acceptance of marijuana evolved further in 2017 with more countries either legalizing cannabis access at a federal level or exploring the possibility of legalizing cannabis.
- Market Realist•6 months ago
Must-Knows before Investing in the Marijuana Industry
Must-Knows before Investing in the Marijuana IndustryInvesting in marijuana
- Marketwired•7 months ago
Corbus Pharmaceuticals Announces Initiation of Phase 2 Study of Anabasum for Treatment of Systemic Lupus Erythematosus
Corbus Pharmaceuticals Holdings, Inc. , a clinical stage drug development company targeting chronic, serious inflammatory and fibrotic diseases, announced today the initiation of a Phase 2 clinical study ...
- Motley Fool•7 months ago
What to Expect From Corbus Pharmaceuticals in 2018
Will the new year bring great results like Corbus had in 2016, or another dismal performance like in 2017?
- Business Insider UK•7 months ago
BRIEF-Corbus Pharmaceuticals Initiates "Resolve-1" Phase 3 Study In Systemic Sclerosis
Dec 14 (Reuters) - Corbus Pharmaceuticals Holdings Inc:
- Marketwired•7 months ago
Corbus Pharmaceuticals Initiates "RESOLVE-1" Phase 3 Study in Systemic Sclerosis
Systemic sclerosis is a rare, serious chronic autoimmune disease with no approved therapyAffects approximately 90,000 individuals in US and EU and associated with 10-year mortality of 40-60%Corbus Pharmaceuticals ...
- Reuters•8 months ago
Insight: High tech, high finance and high times for U.S. pot industry
Gertner is among a growing group of entrepreneurs and investors who are trading in high-paid corporate jobs in the technology and finance sectors to launch start-ups focused on the fast-growing marijuana industry. Two decades after the first legalization of medical marijuana by a U.S. state, pot-based businesses are professionalizing their operations by luring top talent from other industries and billions of dollars in investments from Wall Street firms. The legal cannabis market, currently worth about $8 billion, is predicted to triple in size to $22.6 billion in total annual sales by 2021, according to cannabis industry tracker, Arcview Market Research.
